Your browser doesn't support javascript.
loading
Povidone-iodine in vitro antiseptic efficacy as a function of exposure duration, concentration, preparation, and length of storage.
Ambrosino, Christina M; Shen, Leo L; Mahjoub, Heba; Memon, Warda; Zhang, Sean X; Breazzano, Mark P.
Afiliación
  • Ambrosino CM; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Shen LL; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Mahjoub H; Department of Ophthalmology, Tufts Medical Center, New England Eye Center, Tufts University School of Medicine, Boston, MA, USA.
  • Memon W; Microbiology Laboratory, Johns Hopkins Hospital, Baltimore, MD, USA.
  • Zhang SX; Microbiology Laboratory, Johns Hopkins Hospital, Baltimore, MD, USA.
  • Breazzano MP; Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Graefes Arch Clin Exp Ophthalmol ; 2024 Jul 05.
Article en En | MEDLINE | ID: mdl-38969776
ABSTRACT

PURPOSE:

Although 5% povidone-iodine (PVP-I) is frequently used as an ocular antiseptic agent, there is a lack of consensus regarding the effects of PVP-I concentration, storage after opening, and compounded preparation on PVP-I antisepsis. We performed a series of in-vitro experiments to determine the impact of these factors on PVP-I's inhibition of common causes of post-procedural eye infection.

METHODS:

Inhibition of microorganism growth was measured in-vitro as a function of active PVP-I exposure time. In control experiments, PVP-I was inactivated before microorganism exposure. Tested PVP-I solutions varied in concentration (0.6%, 5%, or 10%), length of storage after opening (0, 7, or 30 days), and preparation (commercial vs.compounded from stock PI solution). Tested pathogens included S. epidermidis, S. viridans, P. aeruginosa, methicillin-resistant S. aureus, methicillin-sensitive S. aureus, and C. albicans.

RESULTS:

PVP-I solutions inhibited all bacterial growth by 3 min and fungal growth by 15 s. Compared to 5% PVP-I, the 0.6% PVP-I was less effective in inhibiting S. viridans growth (200 ± 0 colonies vs. 7 ± 8 at 30 s, P = 0.0004; 183 ± 21 vs. 0 ± 0 at 1 min, P = 0.018), but more effective in inhibiting P. aeruginosa (30 ± 20 vs. 200 ± 0 at 15 s, P = 0.019). Compared to commercial and newly-opened PVP-I solutions, compounded preparations and solutions stored for 7 or 30 days after bottle opening either preserved or improved antiseptic efficacy against tested microorganisms.

CONCLUSIONS:

Concentration of PVP-I solution affects antiseptic efficacy within 1 min of exposure, but all solutions performed equivalently at 3 min. In contrast to results of prior studies investigating dilute PVP-I, the 0.6% PVP-I did not demonstrate a uniformly equivalent or superior anti-septic effect. Compounded preparation and storage length after bottle opening did not decrease PVP-I antiseptic activity.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Graefes Arch Clin Exp Ophthalmol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Graefes Arch Clin Exp Ophthalmol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania